# Female Genital Schistosomiasis Training Competencies

Output from FGS Competency Development workshop July 29-August 13 2020

### 1. Competencies for health professionals in a clinical setting

### 1.1 Diagnose FGS in clinical setting

| #    | Who                    | Does what  | To Whom  | For what  | When   | Required Knowledge   |
|------|------------------------|--|--|---|--|--|
| 1.1a | Health<br>practitioner | Asks about the history/ lifetime risk factors <sup>1</sup> of women and girls that live, have lived, or have traveled in an endemic area   | Women and girls who come to health facilities  | Determine potential<br>exposure to<br>schistosomiasis<br>and risk of FGS  | At every clinical visit by women and girls when appropriate.   | Understand and recall the risk factors for FGS and know to ask family or those accompanying younger girls as appropriate for better history of potential risk      |
| 1.1b | Health<br>practitioner | Asks appropriate questions about FGS symptoms <sup>2</sup> (vaginal discharge, urinary incontinence, blood in urine, irregular vaginal bleeding, postcoital bleeding, lower abdominal pain, infertility), and previous treatment history and outcomes in routine clinical practice | Women and girls<br>potentially at risk of<br>schistosomiasis who<br>come to health facilities                          | Determine if women and girls are experiencing symptoms consistent with FGS or urinary schistosomiasis (bilharzia) | At every clinical visit by women and girls when appropriate.   | Understand and recall the<br>symptoms of FGS as described<br>in the WHO FGS Atlas, and<br>recognize that failed treatment<br>for STI increases suspicion of<br>FGS |
| 1.1c | Health<br>practitioner | Asks about history and symptoms per 1.1a and 1,1b above  | Women and girls that are referred with radiological or histopathological signs   | Determine where schistosomiasis was acquired and who else may be at risk and require follow up                    | When patients<br>referred  | Understand risk factors and symptoms and radiographic and histopathologic signs of FGS   |
| 1.1d | Health<br>practitioner | Elicits history from patient about previous treatment for sexually transmitted infections, infertility, screening for cervical cancer, and previous vaccination for HPV.   | Women who present with<br>blood in urine, clinical<br>symptoms of FGS, or are<br>from an at-risk<br>community/exposure | Differentiate<br>different diseases<br>that may have<br>similar signs and/or<br>symptoms                          | Women present to clinic with blood in urine, clinical symptoms of FGS, or are from an at-risk community or are at risk of exposure | Aware that failed treatment for STIs or cervical cancer can be a sign of FGS   |
| 1.1e | Health<br>practitioner | Orders laboratory diagnostic test for schistosome and STIs per local guidelines  | Women and girls at-risk of FGS with bloody urine, clinical FGS symptoms, and/or a suspected STI                        | Diagnosis of active<br>parasitic infection<br>and differentiate<br>from STI                                       | At clinical visit by women and girls when health   | Understand that even a negative UGS test does not exclude the diagnosis of FGS and praziquantel treatment is still   |

|      |                        |  | not responding to treatment   |   | practitioner deems it appropriate.   | warranted. Know and follow the local guidelines for diagnosis and treatment of STI.   |
|------|------------------------|--|---|---|--|---|
| 1.1f | Health<br>practitioner | Records suspected and confirmed FGS cases and links to care  | Any woman or girl with presumed, suspected, or confirmed FGS diagnosis  | Ensure<br>documentation and<br>reporting of FGS | Any clinical visit   | Understand FGS case definitions, recording, and reporting process   |
| 1.1g | Health<br>practitioner | Refer or confer with a local experienced colleague when in doubt of clinical findings, unable to perform pelvic exam or get adequate visualization in current setting, unclear on treatment, or when presented with a symptomatic patient but pelvic exam is not prudent per local norms and standards | Women and girls (including young or pre- sexually active women/girls) at-risk or with symptoms consistent with pelvic abnormality but unclear diagnosis following visual inspection | Ensure accurate diagnosis                       | During clinical visit or<br>following visual<br>inspection where<br>diagnosis is not clear | Understand limitations of knowledge and understanding and resources available to utilize in assisting with diagnosis and management. Knowledge to administer stat dose of praziquantel. |

### 1.2 Perform pelvic exam to clinically Diagnose FGS

| #    | Who  | Does what  | To Whom   | For what   | When  | Required Knowledge   |
|------|--|--|---|--|---|--|
| 1.2a | Health practitioner who performs pelvic exams with visual inspection with or without colposcope                | Uses a speculum with adequate lighting to inspect every vaginal surface (turn the speculum ninety degrees to inspect the lateral vaginal surfaces) and cervix to identify any lesions and to assess the color, size, and shape | Sexually active women<br>and girls at-risk or with<br>symptoms consistent<br>with pelvic abnormality          | Identify signs of FGS:<br>grainy sandy patches,<br>homogenous yellow<br>patches, rubbery<br>papules, abnormal<br>blood vessels | At clinical visit by<br>women and girls<br>when health<br>practitioner deems<br>it appropriate                            | Recognize FGS signs as contained in WHO Atlas during pelvic exam, when using colposcope or speculum  |
| 1.2b | Health practitioner<br>who performs<br>pelvic exams with<br>visual inspection<br>with or without<br>colposcope | Performs the VIA/VILI procedure and report the local changes of appearance of the lesions and biopsy if indicated.   | Sexually active women<br>and girls at-risk or with<br>symptoms consistent<br>with pelvic abnormality          | Differentiate cervical<br>cancer lesions from<br>other lesions such as<br>FGS lesions  | During clinical visit of women and girls with suspicious lesion on visual inspection or during cervical cancer screening. | Knows how to perform VIA/VILI and recognize lesions at-risk for cervical cancer. Note that lesions that are not shiny white (presentation of cervical cancer) and outside of the transformation zone increase suspicion of FGS |
| 1.2c | Health practitioner who performs pelvic exams with visual inspection with or without colposcope                | Identifies the presence of discharge/<br>history of discharge – smell and<br>color – and treatment for STI's<br>according to local algorithms /<br>management  | Women presenting with<br>blood in urine, clinical<br>symptom of FGS, or<br>from at-risk<br>community/exposure | Differentiate STI that<br>may have similar<br>signs and/or<br>symptoms and<br>ensure proper<br>treatment                       | Women present to clinic with blood in urine, clinical symptom of FGS, or from at-risk community/ exposure                 | Experience with the current treatment of STI   |

#### 1.3 Treat schistosomiasis and FGS

| #    | Who                    | Does what   | To Whom   | For what                              | When   | Required Knowledge  |
|------|------------------------|---|---|---------------------------------------|--|---|
| 1.3a | Health<br>practitioner | Prescribes or administers 40mg/kg of praziquantel as a single dose based on height or weight dosing according to local guidelines and repeats treatment if risk factors persist | A patient diagnosed with FGS or presenting signs and symptoms indicative of FGS (suspected case) or living in or having traveled to an endemic area | To treat<br>schistosomiasis           | Whenever there is<br>a confirmed,<br>suspected, or<br>exposed woman<br>or girl | Understands appropriate treatment<br>for schistosomiasis and FGS, the<br>need for repeated treatment if risk<br>factors persist, and is following<br>current protocols  |
| 1.3b | Health<br>practitioner | Manages or refers for treatment complications of FGS per the WHO FGS Atlas  | A patient suspected or diagnosed with FGS with identified complications   | To treat complications                | Whenever there is<br>a confirmed,<br>suspected, or<br>exposed woman<br>or girl | Is familiar with the possible complications of FGS and adequate treatment or referral for further treatment   |
| 1.3c | Health<br>practitioner | Performs or refers the patient for biopsy or treats according to treatment guidelines if there are aceto-white changes or any suspicion of cancer                               | A patient suspected or diagnosed with FGS in patient with suspicious lesions for cervical cancer  | To prevent or treat cervical cancer   | Whenever there is<br>a confirmed,<br>suspected, or<br>exposed woman<br>or girl | Is familiar with diagnosis and management of cervical cancer  |
| 1.3d | Health<br>practitioner | Informs and counsels the patient about chronicity of established lesions and the higher risk for HIV acquisition if exposed to HIV  | A patient suspected or diagnosed with FGS   | To prevent on<br>HIV and other<br>STI | Whenever there is<br>a confirmed,<br>suspected, or<br>exposed woman<br>or girl | Understands appropriate treatment for schistosomiasis according to local algorithm and is following current protocols for HIV prevention including pre-/post-test counselling   |
| 1.3e | Health<br>practitioner | Informs and counsels the patient that family and community members may also be at risk for schistosomiasis and should seek treatment  | A patient suspected or diagnosed with schistosomiasis or FGS  | To prevent and treat schistosomiasis  | Whenever there is<br>a confirmed,<br>suspected, or<br>exposed woman<br>or girl | Understands risk factors and epidemiology of schistosomiasis and its clinical complications   |
| 1.3f | Health<br>practitioner | Presumptively treats patient with 40mg/kg of praziquantel as a single dose, based on height or weight according to local guidelines   | Women who are presenting with infertility or sub-fertility from an area at risk   | To treat<br>schistosomiasis           | Whenever there is<br>a confirmed,<br>suspected, or<br>exposed woman<br>or girl | Understands appropriate treatment for schistosomiasis and FGS. Understands that treatment may need to be repeated or administered regularly for individuals living in endemic areas with poor water & sanitation facilities |

## 2. Competencies for health professionals in community settings

## 2.1 Identify Women at Risk in the Community

| #    | Who  | Does what  | To Whom  | For what  | When   | Required Knowledge   |
|------|--|--|--|---|--|--|
| 2.1a | Community<br>health<br>worker                      | List communities that are either endemic<br>for schistosomiasis or close to fresh<br>water sources in endemic areas with<br>which community-members may have<br>contact  | Communities  | To identify communities at risk for schistosomiasis | Prior to implementing interventions / action within the community or during micro-planning exercises   | Ability to access and use local health facility data, has knowledge of the disease in the area, and data (epidemiological) from the NTD program at national and sub-national level |
| 2.1b | Community<br>health<br>worker/peer<br>educator     | Assess risk for schistosomiasis infection including questions about routine activities that lead to fresh-water contact in schistosomiasis-endemic areas and other risk behaviors <sup>1</sup>   | Women or girls who are living or have lived in or near schistosomiasisendemic areas  | To identify women or girls at risk of FGS           | During routine household visits or at community health outreach events   | Knowledge of FGS risk factors (i.e. fresh-water contact behavior)  |
| 2.1c | Community<br>health<br>worker/<br>peer<br>educator | Asks questions in a gender and culturally sensitive manner about the presence of typical symptoms <sup>2</sup> of FGS such as vaginal discharge, contact bleeding, history of STIs that do not respond to treatment, and infertility   | Women or girls who<br>are living or have<br>lived in or near<br>schistosomiasis-<br>endemic areas                                  | To identify<br>women or girls<br>at risk of FGS     | During routine household visits or at community health outreach events which specifically target women or perform outreach where women typically congregate in the community | Knowledge of symptoms and ability to address privacy and confidentiality concerns  |
| 2.1d | Community<br>health<br>worker/<br>peer<br>educator | Asks questions in a gender and culturally sensitive manner about any previous history of urinary schistosomiasis or history of STIs that do not respond to treatment   | Women or girls who<br>are living or have<br>lived in or near<br>schistosomiasis-<br>endemic areas                                  | To identify<br>women or girls<br>at risk of FGS     | During routine household visits or at community health outreach events which specifically target women or perform outreach where women typically congregate in the community | Knowledge of FGS risk factors, symptoms, and knowledge of incorrect diagnosis of STIs  |
| 2.1e | Community<br>health<br>worker/<br>peer<br>educator | Identifies communities or community members who do not have access or do not benefit from mass drug administration (if MDA is ongoing) such as school-age children who are not in school, adults at risk, and marginalized individuals (e.g. people living with disabilities, migrants, indigenous groups, etc.) | Community leaders or local opinion leaders and women or girls who are living or have lived in or near schistosomiasisendemic areas | To identify<br>women or girls<br>at risk of FGS     | During routine household visits, at community health outreach events or MDA records (where available)  | Awareness of equity gaps in own community and knowledge of how to obtain praziquantel for schistosomiasis and FGS prevention   |

|      |           |  |                     |                  |                             | Knowledge of FGS risk factors,    |
|------|-----------|--|---------------------|------------------|-----------------------------|-----------------------------------|
|      |           | Recognizes the symptoms of female        |                     | Referral to the  |                             | symptoms, and knowledge of        |
|      | Community | genital schistosomiasis, provides        |                     | community clinic | Interacting at the          | referral options for patients to  |
| 2.1f | health    | counseling, and refers to a local clinic | Women describing    | in order to      | community level during      | get treatment and further         |
|      | worker/   | for treatment and potential pelvic       | symptoms of urinary | reliably treat   | routine household visits or | diagnostic work up. Knowledge     |
|      | peer      | examination or colposcopy after women    | schistosomiasis or  | women at the     | at community health         | of FGS-associated stigma and      |
|      | educator  | describe symptoms of FGS/STIs            | FGS/STIs            | health facility  | outreaches                  | the local socio-cultural context. |

#### 2.2 Prevent schistosomiasis and FGS

| #    | Who  | Does what  | To Whom   | For what   | When  | Required Knowledge  |
|------|--|--|---|--|---|---|
| 2.2a | Community<br>health<br>worker/<br>peer<br>educator | Delivers health education about preventing schistosomiasis and FGS including avoidance of contact with fresh water sources in schistosomiasis -endemic areas and other risk factors <sup>1</sup> , and taking part in mass drug administration (MDA) in the region | At-risk communities<br>(according to<br>guidelines) including<br>women and girls                        | To prevent schistosomiasis and FGS   | During routine household visits or at community health outreach events in schistosomiasis - endemic and surrounding communities | Trained to deliver health education information and knowledgeable about risk factors and prevention of schistosomiasis and FGS  |
| 2.2b | Community<br>health<br>worker                      | Correctly administers praziquantel (PZQ) using a dose pole as a single treatment during community MDA  | At-risk communities<br>(according to<br>guidelines) including<br>women and girls                        | To prevent and treat schistosomiasis   | During community MDA activities   | Trained to deliver MDA for schistosomiasis  |
| 2.2c | Community<br>health<br>worker/<br>peer<br>educator | Delivers treatment or information on where to access praziquantel outside of MDA   | Anyone, especially<br>women or girls, who<br>have not benefited<br>from MDA with or<br>without symptoms | To prevent and treat schistosomiasis   | During routine household visits or at community health outreach events in schistosomiasis-endemic and surrounding communities   | Knowledgeable about risk factors and prevention of schistosomiasis and FGS and referral options for accessing PZQ. Knowledgeable about the need for repeated treatment with PZQ or regular administration of MDA for individuals living in endemic areas with poor water & sanitation facilities. |
| 2.2d | Community<br>health<br>worker<br>/peer<br>educator | Informs and counsels women and girls FGS poses an increased risk of HIV acquisition if exposed to HIV and any other chronic complications of FGS such as infertility and sub-fertility   | Women and girls in schistosomiasis-endemic communities  | To prevent schistosomiasis and HIV   | During routine household visits or at community health outreach events in schistosomiasis-endemic and surrounding communities   | Knowledgeable about schistosomiasis/FGS and link between FGS and HIV acquisition and awareness and sensitivity around potential stigma with that association  |
| 2.2e | Community<br>health<br>worker/<br>peer<br>educator | Delivers health education and counseling on symptoms of FGS and overlap with symptoms of STIs and cervical cancer  | Women in schistosomiasis-endemic communities and their partners   | To prevent FGS<br>and proper<br>treatment for<br>FGS, STI and<br>cervical cancer | During routine household visits or at community health outreach events in schistosomiasis-endemic and surrounding communities   | Knowledgeable about the symptoms of FGS, STIs, and cervical cancer  |

<sup>&</sup>lt;sup>1</sup>Refer to <u>WHO Fact Sheet</u> on schistosomiasis for a list of risk factors and behaviors for schistosomiasis

<sup>&</sup>lt;sup>2</sup>Refer to WHO Atlas for a list of symptoms

<sup>&</sup>lt;sup>3</sup>Recommendation to provide a questionnaire or algorithm to enable CHWs and peer educators to recognize FGS symptoms